Joao Siffert MD - 19 Dec 2022 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Role: President and CEO, Director
Signature: /s/ Mustapha Parekh, Attorney-in-Fact
Issuer symbol: DSGN
Transactions as of: 19 Dec 2022
Net transactions value: +$62,503
Form type: 4
Filing time: 21 Dec 2022, 16:00:16 UTC
Previous filing: 02 Feb 2022
Next filing: 03 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DSGN	Common Stock	Purchase	$9,740	+1,150	+0.92%	$8.47	126,319	19 Dec 2022	Direct	F1
transaction	DSGN	Common Stock	Purchase	$52,762	+6,300	+5%	$8.38	132,619	20 Dec 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,250 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan ("ESPP") on November 15, 2021 and 1,220 shares acquired under the ESPP on May 13, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.32 to $8.44, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth herein.

Content

Includes 1,250 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan ("ESPP") on November 15, 2021 and 1,220 shares acquired under the ESPP on May 13, 2022.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.32 to $8.44, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth herein.